YGT-31
YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model[1].
Product Specifications
CAS Number
2835447-74-8
UNSPSC
12352005
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ygt-31.html
Smiles
OC1=CC(OCC(NCC2=CC=C(C(F)(F)F)C=C2)=O)=CC3=C1C(C=C(O3)C4=CC=CC=C4)=O
Molecular Formula
C25H18F3NO5
Molecular Weight
469.41
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARγ
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GNA12 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
Human Purinergic Receptor P2X 7 (P2RX7) CLIA Kit
Human Purinergic Receptor P2X 7 (P2RX7) CLIA Kit